Arthritis Psoriatic - Symptoms and Treatments

Arthritis Psoriatic is a condition wherein the patient displays both psoriasis, a chronic skin condition, and arthritis. It is estimated that 10 - 30% of people with psoriasis develop psoriatic arthritis. Psoriasis is an inflammation of the skin characterized by patchy, raised, scaly areas. Arthritis is commonly described as an inflammation of the joints.

Arthritis Psoriatic is defined as an autoimmune disorder, in which the body's immune system attacks itself. The cause of this condition is unknown, but genetic, environmental and immune factors may be contributors.

Symptoms of Arthritis Psoriatic are tendon pain, nail deformities, joint pain in the hands, feet, knees and spine, and silvery, dry, scaly patches of skin. Some people with the condition experience burning, itching eyes as well.

People who have Arthritis Psoriatic commonly experience fatigue. Some of the factors causing fatigue are depression, poor sleep habits, inadequate nutrition, anemia, and inflammation. Changing ones' daily schedule, improving diet and exercise, and lowering stress levels may help to alleviate fatigue.

Arthritis Psoriatic

No cure exists for Arthritis Psoriatic, but many treatments are available to try to reduce inflammation and ease pain. There are several categories of drugs for the treatment of Arthritis Psoriatic.

Aspirin and N-SAIDs include both over-the-counter and prescription products, and they help to decrease inflammation. Biologics, such as Enbrel, Humira and Remicade, may relieve more severe symptoms and also slow the progression of psoriatic arthritis. Cortisone injections may relieve pain and improve motion temporarily.

Alternative treatments for Arthritis Psoriatic may also be helpful. One treatment is glucosamine and chondroitin supplements. They are thought to repair cartilage, prevent further deterioration, and reduce pain.

MSM, or methylsulfonylmethane, is believed to have anti-inflammatory properties and is available as a health supplement. SAM-e, or S-adenosylmethionine, helps the body regulate hormones.

Magnet therapy is also mentioned as a possible treatment but should be avoided by pregnant women and people with pacemakers.

Bookmarks

Other Arthritis Psoriatic Items

Risk Of Tuberculosis From Arthritis Medication Examined (Science Daily)

Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis.

Certain arthritis drugs affect TB risk (redOrbit)

The risk of tuberculosis for patients who take arthritis drugs differs from that of the French population at large depending on the agent used, researchers say. Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for TB in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and ...

Certain arthritis drugs affect TB risk (UPI)

PARIS, July 1 (UPI) -- The risk of tuberculosis for patients who take arthritis drugs differs from that of the French population at large depending on the agent used, researchers say.

Congress Advised On Top 100 List Of Health Issues (redOrbit)

An effort enabled by the new economic stimulus package could lead to informing the medical community on which therapies are the most effective in treating a variety of major health issues.Congress has allotted $1.1 billion in order to begin the process of determining the most cost-effective treatments for health problems such as hearing loss, back pain, prostate cancer and irregular ...

Risk of tuberculosis from arthritis medication examined (PhysOrg)

Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening ...

Risk Of Tuberculosis From Arthritis Medication Examined (redOrbit)

Research news from Arthritis & RheumatismTreatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis.

Psoriasis Cure Now Welcomes Institute of Medicine Report Urging 'Comparative Effectiveness' Research on Psoriasis, But ... (redOrbit)

KENSINGTON, Md., June 30 /PRNewswire-USNewswire/ -- "Psoriasis Cure Now," a nonprofit patient advocacy group, today applauded the Institute of Medicine (IOM) for including psoriasis and psoriatic arthritis among its Top 100 health topics meriting priority "comparative effectiveness" research, but the organization expressed concern that treatment rationing could result from the research. The IOM ...

Psoriasis Cure Now Welcomes Institute of Medicine Report Urging 'Comparative Effectiveness' Research on Psoriasis, But ... (PR Newswire via Yahoo! News)

"Psoriasis Cure Now," a nonprofit patient advocacy group, today applauded the Institute of Medicine (IOM) for including psoriasis and psoriatic arthritis among its Top 100 health topics meriting priority "comparative effectiveness" research, but the organization expressed concern that treatment rationing could result from the research.

Biotech Calendar: Key Clinical Trial Dates (TheStreet.com)

Part 3 in our quick-and-dirty guide to upcoming clinical trial dates for drug and biotech companies.

Centocor & Schering-Plough get EMEA's positive opinion for Simponi (PharmaBiz)

Centocor Ortho Biotech Inc and Schering-Plough Corporation announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic ...

Source: